<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30405846</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Print">1837-9664</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>9</Volume>                    <Issue>20</Issue>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Journal of Cancer</Title>                <ISOAbbreviation>J Cancer</ISOAbbreviation>            </Journal>            <ArticleTitle>Paired box 2 promotes progression of endometrial cancer via regulating cell cycle pathway.</ArticleTitle>            <Pagination>                <MedlinePgn>3743-3754</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.7150/jca.22418</ELocationID>            <Abstract>                <AbstractText><b>Background:</b> Human paired box 2 (PAX2) plays a key role in cell fate, early patterning and organogenesis. <b>Methods:</b> We investigated the function of PAX2 on the biological behavior of endometrial cancer in vitro and in vivo and to explore the regulation mechanism, stable knocking-down and over-expression PAX2 endometrial cancer cell lines were established. CCK-8 and transwell assays were applied to determine proliferation, invasion and migration ability. Cell cycle distribution was analyzed by flow cytometry. Affymetrix GeneChipÂ® human Exon 1.0 ST arrays was used to screen the downstream target genes of PAX2. <b>Results:</b> PAX2 significantly enhanced proliferation and invasiveness. In addition, PAX2 influenced the expression of cyclin-dependent kinase 1(CDK1), which play pivotal roles in cell cycle pathway. When CDK1 was knocked down, and the cell proliferation promotion role of PAX2 was attenuated dramatically to a level comparable with the control groups. <b>Conclusions:</b> PAX2, though influencing the expression of CDK1, promotes the proliferation, enhances the mobility of endometrial cancer cells, thus exerts an important role in the carcinogenesis of endometrial cancer. PAX2 may be a potential therapeutic target for endometrial cancer.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Jieyu</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200032, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine-Related Disease of Fudan University, Shanghai, 200011, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jia</LastName>                    <ForeName>Nan</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200032, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine-Related Disease of Fudan University, Shanghai, 200011, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lyv</LastName>                    <ForeName>Tianjiao</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Chao</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200032, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tao</LastName>                    <ForeName>Xiang</ForeName>                    <Initials>X</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200011, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wong</LastName>                    <ForeName>KwongKwok</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Qin</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200032, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Feng</LastName>                    <ForeName>Weiwei</ForeName>                    <Initials>W</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200032, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Shanghai Key Laboratory of Female Reproductive Endocrine-Related Disease of Fudan University, Shanghai, 200011, China.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Obstetrics and Gynecology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>25</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Australia</Country>            <MedlineTA>J Cancer</MedlineTA>            <NlmUniqueID>101535920</NlmUniqueID>            <ISSNLinking>1837-9664</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Cell proliferation</Keyword>            <Keyword MajorTopicYN="N">Ovarian cancer</Keyword>            <Keyword MajorTopicYN="N">PAX2</Keyword>        </KeywordList>        <CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>08</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2017</Year>                <Month>12</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30405846</ArticleId>            <ArticleId IdType="doi">10.7150/jca.22418</ArticleId>            <ArticleId IdType="pii">jcav09p3743</ArticleId>            <ArticleId IdType="pmc">PMC6216001</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>